| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
RESEARCH-ARTICLE |
Faber J, Galløe AM. Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment: a meta-analysis. Eur J Endocrinol 1994;130:350–6. ISSN 0804–4643
L-Thyroxine (L-T4) in the treatment of thyroid disease resulting in reduced serum thyrotropin (TSH) has been associated with reduced bone mass and thus the potential risk of premature development of osteoporosis. However, several recent studies have failed to show such a detrimental effect. These disagreements are probably due to only a small number of patients taking part in each study, decreasing the change of finding significant differences and increasing the risk of missing a real difference (type 1 and 2 errors, respectively). We therefore performed a meta-analysis on the available papers (N = 13), in which bone mass was measured in the distal forearm, femoral neck or lumbar spine in a cross-sectional manner in women with suppressed serum TSH due to L-T4 treatment and in a control group. The women were divided according to their pre- and postmenopausal state, because preserved estrogen production plays a protective role against irreversible bone loss. Based on the number of measurements performed on the different sites of the skeleton, a theoretical bone composed of 30.4% distal forearm, 28.8% femoral neck and 40.8% lumbar spine could be constructed in premenopausal women (441 measurements). A premenopausal woman at an average age of 39.6 years and treated with 164 µg L-T4/day for 8.5 years, leading to suppressed serum TSH, had 2.67% less bone mass than controls (NS), corresponding to an excess annual bone loss of 0.31% after 8.5 years of treatment (NS). The risk of not detecting an excess bone loss of at least 1% per year (type 2 error) was p < 0.15. Similarly, a postmenopausal woman with a bone consisting of 11.3% distal forearm, 42.0% femoral neck and 46.7% lumbar spine (317 measurements) at an average age of 61.2 years and treated with 171 µg L-T4/day for 9.9 years had 9.02% less bone mass than controls (2p < 0.007), corresponding to a significant excess of annual loss of 0.91% after 9.9 years of treatment. Eighteen papers with a mean of 18 patients showing no difference between postmenopausal patients and controls would have to be published or found before this difference could turn into a non-significant finding (the file drawer problem). In conclusion, the meta-analysis on the available crosssectional studies did not find any significant reduction in bone mass during prolonged L-T4 treatment resulting in reduced serum TSH in premenopausal women. The risk of the present meta-analysis missing a clinically relevant annual loss of at least 1% in premenopausal women was less than 15%. In contrast, L-T4 treatment in postmenopausal women in a dosis leading to reduced serum TSH resulted in a significant excess of annual bone loss of 0.91%/year after 9.9 years in comparison to control women.
Jens Faber, Department of Endocrinology E, Frederiksberg Hospital, DK-2000 Frederiksberg, Denmark
This article has been cited by other articles:
|
|
 |
|
  C. B Pham and A. F Shaughnessy Should we treat subclinical hypothyroidism? BMJ, July 16, 2008; 337(jul16_3): a834 - a834. [Full Text]
|
|
|
|
 |
|
 B. Biondi and D. S. Cooper The Clinical Significance of Subclinical Thyroid Dysfunction Endocr. Rev., February 1, 2008; 29(1): 76 - 131. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Wilson, J. V. Parle, L. M. Roberts, A. K. Roalfe, F. D. R. Hobbs, P. Clark, M. C. Sheppard, M. D. Gammage, H. M. Pattison, J. A. Franklyn, et al. Prevalence of Subclinical Thyroid Dysfunction and Its Relation to Socioeconomic Deprivation in the Elderly: A Community-Based Cross-Sectional Survey J. Clin. Endocrinol. Metab., December 1, 2006; 91(12): 4809 - 4816. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. H. Hoogendoorn, A. R. Hermus, F. de Vegt, H. A. Ross, A. L.M. Verbeek, L. A.L.M. Kiemeney, D. W. Swinkels, F. C.G.J. Sweep, and M. den Heijer Thyroid Function and Prevalence of Anti-Thyroperoxidase Antibodies in a Population with Borderline Sufficient Iodine Intake: Influences of Age and Sex Clin. Chem., January 1, 2006; 52(1): 104 - 111. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J L Reverter, S Holgado, N Alonso, I Salinas, M L Granada, and A Sanmarti Lack of deleterious effect on bone mineral density of long-term thyroxine suppressive therapy for differentiated thyroid carcinoma Endocr. Relat. Cancer, December 1, 2005; 12(4): 973 - 981. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K Boelaert and J A Franklyn Thyroid hormone in health and disease J. Endocrinol., October 1, 2005; 187(1): 1 - 15. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Castro and H. Gharib Continuing Controversies in the Management of Thyroid Nodules Ann Intern Med, June 7, 2005; 142(11): 926 - 931. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F Azizi, L Ataie, M Hedayati, Y Mehrabi, and F Sheikholeslami Effect of long-term continuous methimazole treatment of hyperthyroidism: comparison with radioiodine Eur. J. Endocrinol., May 1, 2005; 152(5): 695 - 701. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Biondi, E. A. Palmieri, M. Klain, M. Schlumberger, S. Filetti, and G. Lombardi Subclinical hyperthyroidism: clinical features and treatment options Eur. J. Endocrinol., January 1, 2005; 152(1): 1 - 9. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Mandel A 64-Year-Old Woman With a Thyroid Nodule JAMA, December 1, 2004; 292(21): 2632 - 2642. [Full Text] [PDF]
|
|
|
|
 |
|
 E H Hoogendoorn, M den Heijer, A P J van Dijk, and A R Hermus Subclinical hyperthyroidism: to treat or not to treat? Postgrad. Med. J., July 1, 2004; 80(945): 394 - 398. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Helfand Screening for Subclinical Thyroid Dysfunction in Nonpregnant Adults: A Summary of the Evidence for the U.S. Preventive Services Task Force Ann Intern Med, January 20, 2004; 140(2): 128 - 141. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. I. Surks, E. Ortiz, G. H. Daniels, C. T. Sawin, N. F. Col, R. H. Cobin, J. A. Franklyn, J. M. Hershman, K. D. Burman, M. A. Denke, et al. Subclinical Thyroid Disease: Scientific Review and Guidelines for Diagnosis and Management JAMA, January 14, 2004; 291(2): 228 - 238. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. F. Col, M. I. Surks, and G. H. Daniels Subclinical Thyroid Disease: Clinical Applications JAMA, January 14, 2004; 291(2): 239 - 243. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Crilly Thyroid function tests and hypothyroidism: Reducing concentrations further would be harmful BMJ, May 15, 2003; 326(7398): 1086 - 1086. [Full Text]
|
|
|
|
|
|
J. A. Sgarbi, F. G. Villaca, B. Garbeline, H. E. Villar, and J. H. Romaldini The Effects of Early Antithyroid Therapy for Endogenous Subclinical Hyperthyroidism in Clinical and Heart Abnormalities J. Clin. Endocrinol. Metab., April 1, 2003; 88(4): 1672 - 1677. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Hegedus, S. J. Bonnema, and F. N. Bennedbaek Management of Simple Nodular Goiter: Current Status and Future Perspectives Endocr. Rev., February 1, 2003; 24(1): 102 - 132. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-L. Wemeau, P. Caron, C. Schvartz, J.-L. Schlienger, J. Orgiazzi, C. Cousty, and V. Vlaeminck-Guillem Effects of Thyroid-Stimulating Hormone Suppression with Levothyroxine in Reducing the Volume of Solitary Thyroid Nodules and Improving Extranodular Nonpalpable Changes: A Randomized, Double-Blind, Placebo-Controlled Trial by the French Thyroid Research Group J. Clin. Endocrinol. Metab., November 1, 2002; 87(11): 4928 - 4934. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Castro, P. J. Caraballo, and J. C. Morris Effectiveness of Thyroid Hormone Suppressive Therapy in Benign Solitary Thyroid Nodules: A Meta-Analysis J. Clin. Endocrinol. Metab., September 1, 2002; 87(9): 4154 - 4159. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. C. Sheppard, R. Holder, and J. A. Franklyn Levothyroxine Treatment and Occurrence of Fracture of the Hip Arch Intern Med, February 11, 2002; 162(3): 338 - 343. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Fitts, R. M. Klein, and C. A. Powers Estrogen and Tamoxifen Interplay with T3 in Male Rats: Pharmacologically Distinct Classes of Estrogen Responses Affecting Growth, Bone, and Lipid Metabolism, and Their Relation to Serum GH and IGF-I Endocrinology, October 1, 2001; 142(10): 4223 - 4235. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. F. T. Wesche, M. M. C. Tiel-v Buul, P. Lips, N. J. Smits, and W. M. Wiersinga A Randomized Trial Comparing Levothyroxine with Radioactive Iodine in the Treatment of Sporadic Nontoxic Goiter J. Clin. Endocrinol. Metab., March 1, 2001; 86(3): 998 - 1005. [Abstract] [Full Text]
|
|
|
|
|
|
A C Al-Abadi Subclinical thyrotoxicosis Postgrad. Med. J., January 1, 2001; 77(903): 29 - 29. [Full Text]
|
|
|
|
|
|
P. W. Ladenson, P. A. Singer, K. B. Ain, N. Bagchi, S. T. Bigos, E. G. Levy, S. A. Smith, and G. H. Daniels American Thyroid Association Guidelines for Detection of Thyroid Dysfunction Arch Intern Med, June 12, 2000; 160(11): 1573 - 1575. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Pfeilschifter and I. J. Diel Osteoporosis Due to Cancer Treatment: Pathogenesis and Management J. Clin. Oncol., April 7, 2000; 18(7): 1570 - 1593. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F W F Hanna, J H Lazarus, and M F Scanlon Fortnightly review: Controversial aspects of thyroid disease BMJ, October 2, 1999; 319(7214): 894 - 899. [Full Text]
|
|
|
|
|
|
K. K. Miller and A. Klibanski Amenorrheic Bone Loss J. Clin. Endocrinol. Metab., June 1, 1999; 84(6): 1775 - 1783. [Full Text]
|
|
|
|
|
|
S. L. Greenspan and F. S. Greenspan The Effect of Thyroid Hormone on Skeletal Integrity Ann Intern Med, May 4, 1999; 130(9): 750 - 758. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Hegedüs, B. Nygaard, and J. M. Hansen Is Routine Thyroxine Treatment to Hinder Postoperative Recurrence of Nontoxic Goiter Justified? J. Clin. Endocrinol. Metab., February 1, 1999; 84(2): 756 - 760. [Abstract] [Full Text]
|
|
|
|
 |
|
 Managing subclinical hypothyroidism DTB, January 1, 1998; 36(1): 1 - 3. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. C. Bauer, M. C. Nevitt, B. Ettinger, and K. Stone Low Thyrotropin Levels Are Not Associated with Bone Loss in Older Women: A Prospective Study J. Clin. Endocrinol. Metab., September 1, 1997; 82(9): 2931 - 2936. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A P Weetman Fortnightly review: Hypothyroidism: screening and subclinical disease BMJ, April 19, 1997; 314(7088): 1175 - 1175. [Full Text]
|
|
|
|
|
|
M P J Vanderpump, J A O Ahlquist, J A Franklyn, and R N Clayton Consensus statement for good practice and audit measures in the management of hypothyroidism and hyperthyroidism BMJ, August 31, 1996; 313(7056): 539 - 544. [Full Text]
|
|
|
|
 |
|
 R. D. Utiger Subclinical Hyperthyroidism -- Just a Low Serum Thyrotropin Concentration, or Something More? N. Engl. J. Med., November 10, 1994; 331(19): 1302 - 1303. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
